PT  - JOURNAL ARTICLE
AU  - Geraldes, Ruth
AU  - Juryńczyk, Maciej
AU  - dos Passos, Giordani
AU  - Prichler, Alexander
AU  - Chung, Karen
AU  - Hagens, Marloes
AU  - Ruggieri, Serena
AU  - Huerga, Elena
AU  - Sastre-Garriga, Jaume
AU  - Enzinger, Christian
AU  - Chard, Declan T
AU  - Barkhof, Frederik
AU  - Gasperini, Claudio
AU  - Rovira, Alex
AU  - DeLuca, Gabriele C
AU  - Palace, Jacqueline
ED  - ,
TI  - Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis
AID  - 10.1136/jnnp-2019-322369
DP  - 2020 Apr 01
TA  - Journal of Neurology, Neurosurgery & Psychiatry
PG  - 388--391
VI  - 91
IP  - 4
4099  - http://jnnp.bmj.com/content/91/4/388.short
4100  - http://jnnp.bmj.com/content/91/4/388.full
SO  - J Neurol Neurosurg Psychiatry2020 Apr 01; 91
AB  - Objective To determine if vascular risk factor (VRF), that is, smoking, arterial hypertension (HT), dyslipidaemia and diabetes, have an effect on multiple sclerosis (MS) pathology as measured by MS typical brain lesions, we have compared brain MRIs from patients with MS with and without VRF age-matched and sex-matched.Methods Brain MRIs from five centres were scored for the presence of Dawson’s fingers (DF) and juxtacortical lesions (JCL). A regression model was built to predict the effect of each individual VRF on DF and JCL, considering age and disease duration.Results 92 MS cases without VRF and 106 MS with one or more VRF (80 ever-smokers, 43 hypertensives, 25 dyslipidaemics and 10 diabetics) were included. Ever-smoking associated with a higher burden of DF (Exp(B)=1.29, 95% CI 1.10 to 1.51, p<0.01) and JCL (Exp(B)=1.38, 95% CI 1.21 to 1.57, p<0.01). No other VRF had an impact on DF. Dyslipidaemia associated with increased JCL (Exp(B)=1.30, 95% CI 1.10 to 1.56, p<0.01) but HT did not associate with any of the outcomes.Conclusions Individual VRF appear to affect MS-specific lesions differently. An increase in MS lesions was mainly seen in smokers; however, this VRF is most likely to be present from onset of MS, and other VRF effects may be partly mitigated by treatment. Our findings support that treating VRF and cessation of smoking may be important in the management of MS.